Document is current
Any future updates will be listed below
-
Authors
Pope, Janet E. https://orcid.org/0000-0003-1479-5302
Patel, Jayeshkumar
Saffore, Christopher D.
Fang, Siran
Rasymas, Al
Liazoghli, Dalinda https://orcid.org/0009-0000-0319-6131
Ziouzina, Olga
-
Funding
Funding for this research was provided by:
AbbVie
- License Information
-
More Information
Article History
Received: 17 February 2026
Accepted: 24 April 2026
First Online: 23 May 2026
Declarations
:
: Janet E. Pope has received speaker and advisory board fees from JAK inhibitor companies (Pfizer, Lily, AbbVie, and Gilead Pharmaceuticals). Jayeshkumar Patel, Christopher D. Saffore, Siran Fang, Al Rasymas, and Dalinda Liazoghli are employees of AbbVie and may own stock. Olga Ziouzina has advised and received honoraria or research funding from Amgen, AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, Sandoz, and UCB.
: This study was conducted in accordance with the ethical principles that have their origin in the current Declaration of Helsinki and was consistent with International Conference on Harmonization Good Clinical Practice, Good Epidemiology Practices, and applicable regulatory requirements. All participants provided consent to enroll in the upadacitinib AbbVie Care program and for their demographic and clinical information, as well as questionnaire answers, to be used for research purposes. None of the patients analyzed had their identity or medical records disclosed for the purposes of this study, and only anonymized patient-level data were accessed. Because no identifiable protected health information was extracted or accessed during the course of this study, no institutional review board review or approval was required [ ].
